Cannell Capital’s Burning Rock Biotech BNR Stock Holding History

Cannell Capital’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,624	Closed	-$45.6K	–	70
2023 Q1	$45.6K	Hold	1,624	–	–	0.01%	71
2022 Q4	$36.5K	Hold	1,624	–	–	0.01%	76
2022 Q3	$39K	Buy	1,624 +1,126	+226%	+$36.3K	0.01%	77
2022 Q2	$15K	Buy	+498	New	+$22.2K	﹤0.01%	67

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cannell Capital's BNR Position: Q2 2023 in Review

Cannell Capital sold out of Burning Rock Biotech (BNR) in Q2 2023, closing a stake of 1,624 shares — an estimated $45.6K sold.

Cannell Capital first reported a position in BNR in Q2 2022 and held it in 4 quarters. The position peaked at $45.6K in Q1 2023. 32 funds tracked by Wall St. Rank hold BNR as of Q2 2023.

Cannell Capital reported no remaining Burning Rock Biotech position as of Q2 2023 after selling out during the quarter.
Cannell Capital sold 1,624 Burning Rock Biotech shares in Q2 2023, an estimated $45.6K.
Cannell Capital first reported a position in Burning Rock Biotech in Q2 2022 and held it in 4 quarters.
Cannell Capital's Burning Rock Biotech position peaked at $45.6K in Q1 2023.
32 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.